Market Overview

UPDATE: J.P. Morgan Downgrades Amicus Therapeutics On Cautious View of Migalastat Monotherapy


In a report published Thursday, J.P. Morgan analyst Anupam Rama downgraded Amicus Therapeutics (NASDAQ: FOLD) from an Overweight rating to a Neutral rating.

In the report, J.P. Morgan says "We are downgrading FOLD shares to Neutral from Overweight and removing our $5 December 2014 price target. As expected, based on the 3Q update last week, Amicus announced a number of clinical development, financing, and restructuring updates as well as the acquisition of privately held Callidus Biopharma. From a long-term perspective, we believe yesterday's updates are likely to play out as a net-positive for Amicus, particularly for the Pompe program. Indeed, we believe it is prudent for the company to move forward with Callidus' more potent ERT co-formulated with AT2220. However, while the Pompe program made solid strides in 2013, the next meaningful clinical update is now weighted to 2015. Additionally, Amicus has regained rights to migalastat from GSK globally. We believe migalastat is an active drug in Fabry disease as a monotherapy and, of note, the agent has multiple clinical updates in 2014."

Amicus closed on Wednesday at $2.12.

Latest Ratings for FOLD

Apr 2019Initiates Coverage OnBuy
Jan 2019Initiates Coverage OnOverweight
Jan 2019UpgradesNeutralBuy

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: Anupam Rama J.P. MorganAnalyst Color Downgrades Analyst Ratings


Related Articles (FOLD)

View Comments and Join the Discussion!

Latest Ratings

FNDLoop CapitalMaintains46.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Jefferies Initiates On Toyota Motor On Mediocre CAGR, Overblown Expectations Of Higher Dividends

UPDATE: J.P. Morgan Downgrades J.M. Smucker On Current Revenue Headwinds